Has the outlook improved for amifostine as a clinical radioprotector?
- 1 November 2000
- journal article
- review article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 57 (2) , 113-118
- https://doi.org/10.1016/s0167-8140(00)00235-8
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal modelInternational Journal of Radiation Oncology*Biology*Physics, 1999
- 6 Final report of a phase III randomized trial of amifostine as a radioprotectant in head and neck cancerInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.Journal of Clinical Oncology, 1998
- Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancerAnnals of Oncology, 1998
- Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical ExperiencesEuropean Journal Of Cancer, 1995
- Tumor blood flow changes induced by chemical modifiers of radiation responseInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Is the outlook grey for WR-2721 as a clinical radioprotector?International Journal of Radiation Oncology*Biology*Physics, 1983
- Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumorsInternational Journal of Radiation Oncology*Biology*Physics, 1982
- Radioprotection of mouse skin by WR-2721: The critical influence of oxygen tensionInternational Journal of Radiation Oncology*Biology*Physics, 1982